Abstract
The purpose of the present study was to determine the effects of the beta-2 selective adrenergic agonist albuterol on three behaviors, locomotor activity, behavior maintained under a differential-reinforcement-of-low-rate (DRL) schedule, and behavior maintained under a multiple fixed-interval, fixed-ratio (FI-FR) schedule of reinforcement. Albuterol reduced response rate under the DRL schedule in a manner that resulted in an increase in reinforcement rate. Similarly, albuterol reduced response rate under both components of the multiple FI-FR schedule in a dose-dependent manner. The ED50 values for the effects of albuterol on these two operant behaviors were calculated to be approximately 1 mg/kg and the minimal effective doses were 0.3–1 mg/kg. In addition to affecting operant behavior, albuterol also reduced locomotor activity; the ED50 values and minimal effective doses were 0.05 and 0.03 mg/kg, respectively. The effects of albuterol on DRL behavior, FI-FR behavior and locomotor activity were antagonized by the beta adrenergic antagonist propranolol; this suggests that the behavioral effects of this agonist were mediated, at least in part, by beta adrenergic receptors. The differential sensitivity of locomotor activity and operant behavior to albuterol suggests that the actions of this drug on locomotor activity may be mediated predominantly by peripheral beta adrenergic receptors and that its effects on operant behavior may be mediated by beta adrenergic receptors in the central nervous system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borsini F, Bendotti C, Thurlby P, Samanin R (1982) Evidence that systemically administered salbutamol reduces food intake in rats by acting on central beta adrenergic sites. Life Sci 30:905–911
Caccia S, Fong MH (1983) Kinetics and distribution of the beta adrenergic agonist salbutamol in rat brain. J Pharm Pharmacol 36:200–202
Conway PG, Tejani-Butt S, Brunswick DJ (1987) Interaction of beta adrenergic agonists and antagonists with beta adrenergic receptors in vivo. J Pharmacol Exp Ther 241:755–762
Cook L, Kelleher RT (1962) Drug effects on the behavior of animals. Ann NY Acad Sci 96:315–335
Draper NR, Smith H (1981) Applied regression analysis. Wiley, New York
Enna S, Malick JB, Richelson E (1981) Antidepressants: neurochemical, behavioral, and clinical perspectives. Raven Press, New York
Finnegan KT, Terwilliger MM, Berger PA, Hollister LE, Csernansky JG (1987) A comparison of the neurochemical and behavioral effects of clenbuterol and desipramine. Eur J Pharmacol 134:131–136
Frances H, Poncelet M, Danti S, Goldschmidt P, Simon P (1983) Pharmacological profile of clenbuterol. Drug Dev Res 3:349–356
Geyer MA, Frampton SF (1988) Peripheral mediation of effects of clenbuterol on locomotor and investigatory behavior in rats. Pharmacol Biochem Behav 30:417–420
Lecrubier Y, Puech AJ, Frances H, Jouvent R, Wildlocher D, Simon P (1981) Beta adrenergic stimulation and antidepressant activity. Acta Psychiatr Scand 290:173–178
Lecrubier Y, Puech AJ, Jouvent R, Widlocher D (1980) A beta adrenergic stimulant (salbutamol) versus clomipramine in depression: A controlled study. Br J Psychiatr 136:354–358
Marek GJ, Seiden LS (1988) Selective inhibition of MAO-A but not MAO-B results in antidepressant-like effects on DRL 72-s behavior. Psychopharmacology 96:153–160
Martin LE, Hobson JC, Page JA, Harrison C (1971) Metabolic studies of salbutamol-3H: a new bronchodilator in rat, rabbit, dog, and man. Eur J Pharmacol 14:183–199
Martin P, Soubrie P, Simon P (1986) Shuttle-box deficits induced by inescapable shocks in rats: reversal by the beta adrenoceptor stimulants clenbuterol and salbutamol. Pharmacol Biochem Behav 24:177–181
Martin P, Soubrie P, Simon P (1987) The effect of monoamine oxidase inhibitors compared with classical tricyclic antidepressants on learned helplessness paradigm. Prog Neuropsychopharmacol Biol Psychiatr 11:1–7
McElroy JF, O'Donnell JM (1988) Discriminative stimulus properties of clenbuterol: Evidence for beta adrenergic involvement. J Pharmacol Exp Ther 245:155–163
McElroy JF, Stimmel JJ, O'Donnell JM (1989) Effects of centrally acting beta adrenergic agonists on discrete trial conditioned avoidance behavior in rats. Psychopharmacology 97:108–114
McGuire PS, Seiden LS (1980) Differential effects of imipramine in rats as a function of DRL schedule value. Pharmacol Biochem Behav 13:691–694
McKearney JW (1968) The relative effects ofd-amphetamine, imipramine and harmaline on tetrabenazine suppression of schedule-controlled behavior in the rat. J Pharmacol Exp Ther 159:429–440
Minneman KP, Hegstrand LR, Molinoff PB (1979) The pharmacological specificity of beta-1 and beta-2 adrenergic receptors in rat heart and lung. Mol Pharmacol 16:21–33
Molinengo L, Ricci-Gamalero S (1972) The action of imipramine, amitriptyline, doxepin, and butriptyline in an operant conditioning schedule. Psychopharmacologia 24:247–257
O'Donnell JM (1987a) Effects of clenbuterol and prenalterol on performance during differential reinforcement of low response rate in the rat. J Pharmacol Exp Ther 241:68–75
O'Donnell JM (1987b) Effects of clenbuterol and prenalterol on behavior maintained under a multiple fixed-interval, fixed-ratio schedule. J Pharmacol Exp Ther 242:558–594
O'Donnell JM (1988a) Psychopharmacological consequences of activation of beta adrenergic receptors by SOM-1122. J Pharmacol Exp Ther 246:38–46
O'Donnell JM (1988b) Behavioral consequences of activation of beta adrenergic receptors: Evidence for mediation by the central nervous system. Brain Res Bull 21:491–497
O'Donnell JM (1990) Behavioral effects of beta adrenergic agonists and antidepressants after down-regulation of beta-2 adrenergic receptors. J Pharmacol Exp Ther 254:147–157
O'Donnell JM (1993) Effects of the centrally acting beta-2 adrenergic agonist zinterol on DRL behavior and locomotor activity. Psychopharmacology (in press)
O'Donnell JM, Seiden LS (1983) Differential-reinforcement-of-low-response-rate 72-second schedule: selective effects of antidepressant drugs. J Pharmacol Exp Ther 224:80–88
Ordway GA, Gambarana C, Frazer A (1988) Quantitative autoradiography of central beta adrenoceptor subtypes: comparison of the effects of chronic treatment with desipramine or centrally administered isoproterenol. J Pharmacol Exp Ther 247:379–389
Seiden LS, Marek GJ, O'Donnell JM, Li A, Dunn R, Jolly D (1988) The role of noradrenergic and serotonergic systems in the screening of antidepressant drugs. In: Sandler M (ed) Progress in catecholamine research: clinical aspects. Liss, New York, pp 337–342
Seiden LS, O'Donnell JM (1985) The effects of antidepressant drugs on DRL behavior. In: Seiden LS, Balster R (eds) Behavioral pharmacology: The current status. Liss, New York, pp 323–338
Simon P, Lecrubier Y, Jouvent R, Puech A, Widlocher D (1984) Beta receptor stimulation in the treatment of depression. Adv Biochem Psychopharmacology 39:293–299
Snapper AG, Kadden RM, Inglis GB (1982) State notation of behavioral procedures. Behav Res Methods Instrum 14:329–343
Winer BJ (1971) Statistical principles in experimental design. McGraw Hill, New York
Zini R, Morin D, Martin P, Puech AJ, Tillement JP (1991) Interactions of flerobuterol, an antidepressant drug candidate, with beta adrenoceptors in rat brain. J Pharmacol Exp Ther 259:414–422
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Donnell, J.M. Differential sensitivity to the effects of albuterol on locomotor activity and operant behavior. Psychopharmacology 113, 243–249 (1993). https://doi.org/10.1007/BF02245705
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245705